Deals In Depth: March 2013
Executive Summary
AstraZeneca paid $240 million for rights to Moderna’s RNA therapeutics. Argon Medical acquired Angiotech’s interventional business for $362.5 million. PIPEs accounted for 31% of the $976 million in biopharma financing. FOPOs, on the other hand, dominated the $523 million in device fundraising.
You may also be interested in...
AliveCor’s Smartphone-Linked ECG First Product Assessed Under UK’s Rapid HTA Pilot
NICE’s recently launched early value assessment (EVA) pilot has hit a milestone this month, with AliveCor’s KardiaMobile 6L the first product to be given the go-ahead for NHS use in England under the scheme.
Vibrant IVDs Innovation Climate At Risk From Poor UK Regulatory System Readiness
The spotlight is on IVDs in the post-COVID phase. Innovators in university spin-outs and the established industry have responded with new technologies, creating a vibrant scene. Regulators and reimbursors must not disrupt the momentum, say BIVDA’s regulatory affairs manager Ashleigh Batchen and chief executive Doris-Ann Williams.
The Generics Bulletin Top 50, Part Two: Mid-Table Movements See Firms Jostle For Position
Medium-sized generics and biosimilars players have seen ups and downs over the past year, with some changes to the order of these mid-table players seen as we continue to work our way through Generics Bulletin’s annual Top 50.